Background/Aims: This study analyzed the scale and trends of the social and economic costs of liver disease in Korea for the past 5 years. Methods: The social aspects of socioeconomic costs were projected for viral hepatitis (B15-B19), liver cirrhosis, malignant neoplasm of the liver (C22) and other liver diseases (K70-K76), as representative diseases by dividing costs into direct and indirect from 2004 to 2008. Direct costs include hospitalization, outpatient, and pharmacy costs in the health-care sector, and transportation and caregiver costs. Indirect costs include the future income loss due to premature death and the loss of productivity resulting from absence from work. Results: The social and economic costs of liver disease were projected to be KRW 5,858 billion in 2004, KRW 5,572 billion in 2005, KRW 8,104 billion in 2006, KRW 6,095 billion in 2007, and KRW 5,689 billion in 2008. The future income loss resulting from premature death is thus greatest, from 73.9% to 86.1%, followed by the direct medical costs, from 9.0% to 18.1%. The productivity loss resulting from absence from work accounts for 3.3-5.5%, followed by the direct nonmedical costs such as transportation and caregiver costs, at 1.5-2.5%. Conclusions: Among the socioeconomic costs of liver disease in Korea, the future income loss resulting from premature death is showing a decreasing trend, whereas direct medical costs are increasing dramatically. 
INTRODUCTION
As the human life span has been extended with the development of medicine, chronic diseases rather than acute ones have been increasing. Because it is hard to cure chronic liver disease completely and it should be controlled well for life, patients and their family members bear various burdens.
Liver disease, one of the most representative chronic diseases, has showed a high prevalence rate in the East including South Korea and it includes chronic hepatitis, hepatic cirrhosis and hepatocellular carcinoma (HCC).
Liver disease ranked the eighth among causes of death in South Korea in 2009, and 6,868 died of liver disease for the one year. 1 It recorded adds the cause of fifth in males and did third in persons in their 40s. Moreover, the mortality rate of HCC showed the second highest level by following lung cancer and it did the highest in persons in their 40s and 50s. 1 In particular, a study estimating socioeconomic costs of major cause of death in South Korea revealed that the loss of productivity caused by premature death due to chronic liver disease ranked second next to that of cancer. 2 The high mortality of liver disease in economically active persons in their 40s and 50s means that the importance of liver disease management should be recognized by considering that chronic liver disease influences not only individuals or families but also the productivity of a society. 3 The cost of illness is one of the most initial economic evaluation methods in the healthcare and it aims to measure the economic burden of illness in a society in terms of the consumption of healthcare resources and the loss of productivity. 4 In addition, studies on the cost of illness suggest the negative influence of illness and injury by using have problem relating to validity or reliability. 5, 6 Nonetheless, studies on the cost of illness have been utilized as important indexes to prioritize the economic burdens of specific diseases, to determine the priority of research and development in National Institutes of Health, Institute of Medicine, the national assembly and others. 6 Most previous studies on the cost of illness have dealt with major health risks like specific diseases 2, 7, 8 or smoking, [9] [10] [11] [12] alcohol-drinking [13] [14] [15] and obesity [16] [17] [18] and their relevant diseases. But, even though liver disease exerts not a few negative effect in South Korea with recording a high mortality rate especially in economically active age groups as one of major death causes, there has been nearly no study analyzing the socioeconomic burden of liver disease precisely in the country. Therefore, this study aims to estimate the socioeconomic costs of major liver diseases 
MATERIALS AND METHODS

Materials
Studies on the cost of illness have been described by several researchers since 1960s. 6, [19] [20] [21] Generally, studies on the cost of illness divide costs into direct, indirect and intangible ones and their viewpoints include a society, governmental institutions, employers, program providers and others. Most studies have measured the cost of illness from a societal perspective to consider its overall change comprehensively. 22 This study selected viral hepatitis (B15-B19), liver cirrhosis and others (K70-K76) and HCC (C22) ( Table 1) 
Direct costs
The direct costs included direct medical costs and direct non-medical costs. 
Indirect costs
Indirect costs included lost earnings due to premature death caused by liver disease and loss of productivity following absences from work to visit medical institutions. 
RESULTS
Direct costs
The medical costs of inpatients and outpatients at medical institutions and at pharmacies to treat liver disease or the sum of benefits paid by the insurer, legal out-of pocket payments and uninsured out-of pocket payments, increased (Table 9) .
DISCUSSION
Liver disease is one of major death causes in South Korea and the number of deaths caused by it tends to be high in economically active age groups as a representative disease provoking a significant loss of productivity due to premature death. In 2001, liver disease ranked fifth among death causes in South Korea but its loss of productivity due to premature death was found to be the highest except cancer which is the By the cost items, the lost earnings caused by liver disease-related premature death accounted for the largest portion of the total costs or 73.9-86.1%, and the direct medical costs (9.0-18.1%), the loss of productivity following sick leave (3.3-5.5%) and the traffic costs and the costs of caregivers (1.5-2.5%) followed it in the order. respectively. For liver disease, the lost earnings due to premature death accounted for 88.3% of the total costs and rates of the medical expenditures of inpatients and outpatients, the costs of lost workdays, the costs of caregivers and the traffic costs recorded 7.7%, 2.4%, 1.1%
and 0.5%, respectively.
In the comparison of the results between their study and this one, the study of Jung and Ko 2 showed that the socioeconomic costs of liver disease were estimated to be KRW 2,620.1 billion in 2001 while this study found that the costs were done to be KRW 5,858 billion in 2004, so the difference in the costs was significant. That is considered to result from not only the difference in the year of estimation and the methodologies but also the exclusion of the costs at pharmacies, which accounted for a considerable portion in the total costs, in the study of Jung and Ko. 2 But, the finding that the rate of lost earnings due to premature death recorded the highest level among the socioeconomic costs of liver disease and the lost earnings by age showed the highest rates in economically active persons in their 30s, 40s and 50s, tended to be similar in both of the two studies and it led to a large influence on the loss of productivity in the society at large.
In addition, studies estimating the socioeconomic costs of disease have been reported continuously in Canada since 1986. A study calculating the socioeconomic costs by classifying total disease into 20 groups such as cardiovascular disease, musculoskeletal disease and cancer with the data in 1998 was published. 34 The study in Canada 34 largely divided the costs of diseases into direct and indirect costs, and the direct costs included treatment amount at medical institutions, drug expenditures and doctor bills and the indirect costs contained death costs and costs of prevalence of short-and long-term disorder. According to its results, although it did not examine liver disease specifically, the direct and indirect 
